On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering

Company: enVVeno Medical Corporation (NVNO)
Category: News

enVVeno Medical (NASDAQ: NVNO), a late-clinical stage medical device company setting new standards of care for the treatment of venous diseases, recently announced the pricing of an underwritten public offering. Led by existing institutional investors, the offering involved the issuance and sale of 4,285,715 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per unit. enVVeno expected to receive aggregate gross proceeds from the offering of about $15.0 million. The offering was anticipated to close on or about September 30, 2024, subject to customary closing conditions.

To view the full press release, visit https://nnw.fm/cslZd

About enVVeno Medical Corporation

enVVeno Medical is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company’s lead product, the VenoValve(R), is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (“CVI”). The company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe(R). CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve(R) and enVVe(R) are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve(R) is currently being evaluated in the SAVVE U.S. pivotal trial and the company is currently performing the final testing necessary to seek approval for the enVVe(R) pivotal trial.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217